Nutraceutical effects of Emblica officinalis in age-related macular degeneration

Nashine, Sonali; Kanodia, Raj; Nesburn, Anthony B.; Soman, Girish; Kuppermann, Baruch D.; Kenney, M. Cristina

doi:10.18632/aging.101820

Cited by 27 publications

(16 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All AMD patients used in this study have been clinically characterized, and genetic and clinical information of all patients is available as partly mentioned in Table 1. Morphological and functional evaluation of these AMD RPE transmitochondrial cell lines in our previous studies revealed significant mitochondrial and cellular damage as evidenced by apoptotic cell death, higher oxidative stress, low antioxidant content, lower numbers of mitochondria, and higher mtDNA fragmentation in AMD RPE cells [9][10][11][12][13]. Therefore, AMD RPE transmitochondrial cell lines serve as a good in vitro model to test the effects of resveratrol as a potential over-the-counter candidate for AMD therapy.…”

Section: Discussionmentioning

confidence: 94%

Role of Resveratrol in Transmitochondrial AMD RPE Cells

et al. 2020

Self Cite

View full text Add to dashboard Cite

Resveratrol is a phytoalexin, stilbenoid compound with antioxidant properties attributable to its bioactive trans-resveratrol content. This study characterized the effects of over-the-counter (OTC) resveratrol nutritional supplements and a HPLC-purified resveratrol formulation, in human transmitochondrial age-related macular degeneration (AMD) retinal pigment epithelial (RPE) patient cell lines. These cell lines, which were created by fusing blood platelets obtained from dry and wet AMD patients with mitochondria-deficient (Rho0) ARPE-19 cells, had identical nuclei (derived from ARPE-19 cells) but different mitochondria that were derived from AMD patients. After resveratrol treatment, the levels of cell viability and reactive oxygen species production were measured. Results demonstrated that treatment with different resveratrol formulations improved cell viability and decreased reactive oxygen species generation in each AMD patient cell line. Although further studies are required to establish the cytoprotective potential of resveratrol under different physiological conditions, this novel study established the positive effects of OTC resveratrol supplements in macular degeneration patient cybrid cell lines in vitro.

show abstract

Section: Discussionmentioning

confidence: 94%

Role of Resveratrol in Transmitochondrial AMD RPE Cells

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…IncuCyte live-cell imaging was performed as described previously [69]. The IncuCyte NucLight Rapid Red Reagent is a cell permeable DNA stain that specifically stains nuclei in live cells and enables real-time quantification of cell proliferation.…”

Section: Methodsmentioning

confidence: 99%

PU-91 drug rescues human age-related macular degeneration RPE cells; implications for AMD therapeutics

Nashine

Subramaniam

Chwa

et al. 2019

Aging

Self Cite

View full text Add to dashboard Cite

Since mitochondrial dysfunction is implicated in the pathogenesis of AMD, this study is based on the premise that repurposing of mitochondria-stabilizing FDA-approved drugs such as PU-91, might rescue AMD RPE cells from AMD mitochondria-induced damage. The PU-91 drug upregulates PGC-1α which is a critical regulator of mitochondrial biogenesis. Herein, we tested the therapeutic potential of PU-91 drug and examined the additive effects of treatment with PU-91 and esterase inhibitors i.e., EI-12 and EI-78, using the in vitro transmitochondrial AMD cell model. This model was created by fusing platelets obtained from AMD patients with Rho0 i.e., mitochondria-deficient, ARPE-19 cell lines. The resulting AMD RPE cell lines have identical nuclei but differ in their mitochondrial DNA content, which is derived from individual AMD patients. Briefly, we report significant improvement in cell survival, mitochondrial health, and antioxidant potential in PU-91-treated AMD RPE cells compared to their untreated counterparts. In conclusion, this study identifies PU 91 as a therapeutic candidate drug for AMD and repurposing of PU-91 will be a smoother transition from lab bench to clinic since the pharmacological profiles of PU-91 have been examined already.

show abstract

“…Biological source: Emblica officinalis Immunity boosting mechanism: It is a rich source of antioxidants, including polyphenols, which confer its free radical scavenging potential (56). 1349 13) Guduchi: Biological source: Tinospora cordifolia Immunity boosting mechanism: It increases the concentration of cytokines.…”

Section: ) Amlamentioning

confidence: 99%